MAYO CLINIC LABORATORIES

1-800-533-1710

MPNR

Myeloproliferative Neoplasm, JAK2 V617F with Reflex to CALR and MPL, Varies

Patient ID	Patient Name		Birth Date	Sex	Age
SA00181998	TESTINGRNV, MPNR A		2001-01-01	M	25
Order Number	**Client Order Number**	**Ordering Physician**	**Report Notes**		
SA00181998	SA00181998	CLIENT,CLIENT			
Account Information		**Collected**			
C7028846 DLMP Rochester		28 Oct 2026 00:00			

MPN (JAK2 V617F, CALR, MPL) Reflex

MPNR Result

MCR

see interpretation

Final Diagnosis

1 MCR

Peripheral blood, CALR mutation analysis, exon 9:

Positive. A 5bp insertion-type mutation was detected in CALR, exon 9.

Comment: CALR mutation is identified in approximately 49–88% of JAK2 and MPL-wild type essential thrombocythemia (ET) and primary myelofibrosis (PMF) patients, and at significantly lower frequencies in other myeloid neoplasms such as refractory anemia with ringed sideroblasts associated with marked thrombocytosis (13%), myelodysplastic syndrome (8%), chronic myelomonocytic leukemia (3%) or atypical chronic myeloid leukemia (3%) (Klampfl et al., 2013, 24325356; Nangalia et al., 2013, 24325359). Correlation with clinical and pathologic findings is required for a definitive diagnosis.

No further testing for MPL mutation was performed as it is not indicated per MPNR test algorithm. See test catalogue for additional information.

Method summary - CALR: Exon 9 of CALR was amplified from genomic DNA by polymerase chain reaction (PCR). The size of the PCR product was analyzed by capillary electrophoresis. The analytic sensitivity of this assay is approximately 6% for the majority of CALR mutations and is approximately 20% for the rare type 1-bp deletion.

Peripheral blood, JAK2 V617F mutation analysis:

Negative for JAK2 V617F.

Method summary - JAK2 V617F analysis: Quantitative, allele-specific polymerase chain reaction (PCR) assay was performed using extracted genomic DNA to evaluate for the point mutation causing JAK2 V617F. The analytic sensitivity of this assay has been determined at 0.06%.

Signing Pathologist: LAUREN SCHULTZ

Received: 28 Oct 2026 06:30 **Reported:** 28 Oct 2026 06:48

Environment LTCSEQ Template

Laboratory Notes

1 This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905	Nikola Baumann Ph.D.	24D0404292